However, as we demonstrate here in a large tumor dataset, we found that GLS1 is not overexpressed in clinical specimens of OCCC that are negative for ARID1A and that on the contrary, ARID1A-positive tumors have higher levels of GLS1 as compared to patients who are ARID1A negative. Here, ARID1A is linked to neoplasm.